Oncolytics Biotech (ONCY) Depreciation & Amortization (CF) (2009 - 2025)

Oncolytics Biotech (ONCY) has 17 years of Depreciation & Amortization (CF) data on file, last reported at $17439.2 in Q3 2025.

• On a quarterly basis, Depreciation & Amortization (CF) fell 33.92% year-over-year to $17439.2 in Q3 2025; TTM through Dec 2025 was $53601.9, a 38.87% decrease from a year earlier, with the FY2025 full-year figure at $70000.0, down 20.14% from the prior year.
• Depreciation & Amortization (CF) for Q3 2025 stood at $17439.2, down from $18042.8 in the prior quarter.
• Over the last five years, Depreciation & Amortization (CF) for ONCY reached as high as $61291.1 in Q2 2021 and fell as low as $8809.2 in Q3 2021.
• Historically, Depreciation & Amortization (CF) has averaged $19856.1 across 5 years, with a median of $18042.8 in 2025.
• Across the five-year window, Depreciation & Amortization (CF) jumped 276.3% in 2021 and slumped 69.74% in 2022, its largest moves.
• Year by year, Depreciation & Amortization (CF) stood at $18263.4 in 2021, then fell by 11.26% to $16207.5 in 2022, then decreased by 13.89% to $13956.2 in 2023, then jumped by 43.62% to $20043.8 in 2024, then retreated by 12.99% to $17439.2 in 2025.
• Per Business Quant data, the three most recent Depreciation & Amortization (CF) figures were $17439.2 in Q3 2025, $18042.8 in Q2 2025, and $18119.8 in Q1 2025.